Advocating for you — Removing barriers to medications
The health care system is often unpredictable but still demands the best patient care at the right time. You collaborated with us to quickly address policy changes affecting claims and formularies.
When Anthem and Empire Blue Cross Blue Shield announced a formulary change that excluded ixekizumab (Taltz), you brought us serious concerns over this nonmedical switching effort, and we worked with Anthem explaining the threat to psoriasis patients. Ultimately, Anthem grandfathered in patients stable on Taltz and confirmed they could remain on the drug.
When we learned that Blue Shield of California had a policy restricting dermatologists from prescribing omalizumab (Xolair), resulting in prior authorization denials, we successfully advocated to BSCA to reverse this policy.
We work with you to ensure payer policies align with your everyday practice, so you can get back to treating patients.
